Solving the Evidence Interpretability Crisis in Health Technology Assessment: A Role for Mechanistic Models?

Abstract

Health technology assessment (HTA) aims to be a systematic, transparent, unbiased synthesis of clinical efficacy, safety, and value of medical products (MPs) to help policymakers, payers, clinicians, and industry to make informed decisions. The evidence available for HTA has gaps—impeding timely prediction of the individual long-term effect in real clinical practice. Also, appraisal of an MP needs cross-stakeholder communication and engagement. Both aspects may benefit from extended use of modeling and simulation. Modeling is used in HTA for data-synthesis and health-economic projections. In parallel, regulatory consideration of model informed drug development (MIDD) has brought attention to mechanistic modeling techniques that could in fact be relevant for HTA. The ability to extrapolate and generate personalized predictions renders the mechanistic MIDD approaches suitable to support translation between clinical trial data into real-world evidence. In this perspective, we therefore discuss concrete examples of how mechanistic models could address HTA-related questions. We shed light on different stakeholder's contributions and needs in the appraisal phase and suggest how mechanistic modeling strategies and reporting can contribute to this effort. There are still barriers dissecting the HTA space and the clinical development space with regard to modeling: lack of an adapted model validation framework for decision-making process, inconsistent and unclear support by stakeholders, limited generalizable use cases, and absence of appropriate incentives. To address this challenge, we suggest to intensify the collaboration between competent authorities, drug developers and modelers with the aim to implement mechanistic models central in the evidence generation, synthesis, and appraisal of HTA so that the totality of mechanistic and clinical evidence can be leveraged by all relevant stakeholders.

A quantitative systems pharmacology workflow toward optimal design and biomarker stratification of atopic dermatitis clinical trials

“…Adjusting the dose and the treatment to each patient's individual characteristics are the guiding principles of personalized medicine. Yet, today the gold standard for the approval of new drugs by regulatory agencies are placebo-controlled randomized clinical trials that report efficacy of 24/43 entire populations of patients (see our discussion in Courcelles et al 102 from a health technology assessment perspective). A way to better individualize drug development could be to use patient stratification and subgroup analysis, optimally performed on the basis of easily measurable biomarkers as objective (and ideally validated) predictors of treatment effect (predictive biomarkers).…”

Empirical methods for the validation of Time-To-Event mathematical models taking into account uncertainty and variability: Application to EGFR+ Lung Adenocarcinoma

“…Based upon knowledge in the literature describing components of biology which are integrated using fundamental laws of nature such as physical and biochemical principles, these models allow representation and analysis of complex dynamic behavior of variables seen in biology and clinical trials 1, 2 . During the past decade, mechanistic models have been progressively integrated into the pharmaceutical research and development industry workflow to provide valuable decision support in addition to conventional in vitro and in vivo approaches 3 4 .…”